Cargando…

Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer

SIMPLE SUMMARY: The prognosis of non-small cell lung cancer (NSCLC) is poor as more than half of the patients are diagnosed at an advanced stage. The outcomes have greatly improved in the recent two decades due to the introduction of target therapy. Anaplastic lymphoma kinase (ALK) rearrangement is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chuang, Cheng-Hao, Chen, Hsiao-Ling, Chang, Hsiu-Mei, Tsai, Yu-Chen, Wu, Kuan-Li, Chen, I-Hua, Chen, Kung-Chao, Lee, Jui-Ying, Chang, Yong-Chieh, Chen, Chin-Ling, Tu, Yu-Kang, Hung, Jen-Yu, Yang, Chih-Jen, Chong, Inn-Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072703/ https://www.ncbi.nlm.nih.gov/pubmed/33921762 http://dx.doi.org/10.3390/cancers13081966

Ejemplares similares

First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis
por: Wu, Kuan-Li, et al.
Publicado: (2021)

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
por: Zheng, Zhe-Rong, et al.
Publicado: (2023)

Salvage Therapy for Relapsed Malignant Pleural Mesothelioma: A Systematic Review and Network Meta-Analysis
por: Tsai, Yu-Chen, et al.
Publicado: (2021)

Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis
por: Lee, Tai-Huang, et al.
Publicado: (2022)

Small cell variant of ALK-positive anaplastic large cell lymphoma with primary subcutaneous presentation: A case report
por: Jaing, Tang-Her, et al.
Publicado: (2018)

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
por: Stadler, Serena, et al.
Publicado: (2018)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
por: Wang, Yuan, et al.
Publicado: (2022)

NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
por: Haque, Moinul, et al.
Publicado: (2019)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
por: Tan, Daniel S.W., et al.
Publicado: (2020)

Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma
por: Chen, Hsiao-Ling, et al.
Publicado: (2020)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

ALK+ Anaplastic Large Cell Lymphoma of Null Cell Phenotype with Leukemic Transformation and Leukemoid Reaction
por: Chuang, Shih-Sung, et al.
Publicado: (2019)

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
por: Zdzalik, Daria, et al.
Publicado: (2014)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
por: Singh, Abhay, et al.
Publicado: (2020)

Pathobiology of ALK-negative anaplastic large cell lymphoma
por: Pileri, Stefano A., et al.
Publicado: (2011)

ALK-positive anaplastic large cell lymphoma in adults
por: Gromowsky, Matthew J, et al.
Publicado: (2023)

Electrochemical Hydroxylation of C(3)–C(12)n-Alkanes by Recombinant Alkane Hydroxylase (AlkB) and Rubredoxin-2 (AlkG) from Pseudomonas putida GPo1
por: Tsai, Yi-Fang, et al.
Publicado: (2017)

22. COMPARATIVE EFFICACY OF ALK-INHIBITORS IN ALK INHIBITOR-NAIVE ALK+ LUNG CANCER BRAIN METASTASES: A NETWORK META-ANALYSIS
por: Haddad, Philip, et al.
Publicado: (2020)

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
por: Singh, Vijay Kumar, et al.
Publicado: (2019)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Primary cutaneous ALK-negative anaplastic large cell lymphoma: A case report
por: Zhu, Xin-Yu, et al.
Publicado: (2023)

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma
por: Tabbó, Fabrizio, et al.
Publicado: (2012)

Educational Case: ALK-Negative Anaplastic Large Cell Lymphoma
por: Satou, Akira, et al.
Publicado: (2020)

Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
por: Lin, Liping, et al.
Publicado: (2018)

Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma
por: Hu, G, et al.
Publicado: (2017)

ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment
por: Chioureas, Dimitrios, et al.
Publicado: (2022)

ALK-positive anaplastic large cell lymphoma with prominent bone involvement in a 13-year-old boy
por: Tian, Chen, et al.
Publicado: (2016)

Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review
por: Chen, Monica F., et al.
Publicado: (2023)

Genetic Dissection and Functional Differentiation of ALK(a) and ALK(b), Two Natural Alleles of the ALK/SSIIa Gene, Responding to Low Gelatinization Temperature in Rice
por: Chen, Zhuanzhuan, et al.
Publicado: (2020)

Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease
por: Lawrence, Kasey, et al.
Publicado: (2015)

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787
por: Parker, Aulma R, et al.
Publicado: (2015)

An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
por: Turner, Suzanne D.
Publicado: (2017)

ALK-positive anaplastic large cell lymphoma with soft tissue involvement in a young woman
por: Gao, Kehai, et al.
Publicado: (2016)

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor()
por: Chen, Xinru, et al.
Publicado: (2017)

Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma
por: Krishnamurthy, Savitri, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_09t1bafogsi98p6251pi01c4le